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ABSTRACT Patients with neoplasia who are severely immunocompromised have a 
higher risk of fungal infections. There are limited data in the literature regarding the 
frequency of dermatophyte infections and efficacy of antifungals in patients with 
malignancies.
Objective was assessment of the incidence of dermatophyte infections and anti-
fungal susceptibility, determination of dermatophyte species isolated from patients 
with neoplastic diseases. 138 patients diagnosed with various malignancies and 160 
immunocompetent patients who were referred to the Department of Dermatology 
in Brasov, Romania, for suspicion of dermatophyte infections were included in the 
study. Nail clippings or skin scrapings were examined by direct microscopy and cul-
tures in Sabouraud agar medium. Susceptibility tests for antifungals were conducted 
in vitro using a method of broth microdilution.  Infections with dermatophytes were 
identified in 30.4% of patients with neoplastic diseases and in 29.37% in the con-
trol group. There was a significantly higher frequency of dermatophyte infections 
in patients with hematologic malignancies (52%) compared to those with solid can-
cers (25.66%) (P=0.01). The clinical aspects of dermatophyte infections in patients 
with neoplastic diseases were not different from those of patients without cancer; 
though in some cases the infections were more extensive. There were no statistically 
significant differences between mean values of minimum inhibitory concentration of 
antifungals compared with controls. Terbinafine had the highest antidermatophyte 
activity for all tested dermatophyte species isolated from patients with neoplastic 
diseases.
There were no differences in frequency of dermatophyte infections and antifungal 
susceptibility to dermatophytes between patients with neoplastic diseases and im-
munocompetent patients.
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INTRODUCTION 
The prevalence of fungal infections has increased 
significantly in recent decades mainly due to the in-
creasing number of immunocompromised patients. 
Risk factors such as population aging or increased 
incidence of certain diseases such as human immu-
nodeficiency virus (HIV) infection, diabetes mellitus, 
malignancies, or immunosuppressive therapies has 
led to an increasing incidence of fungal infections. 
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Patients with malignancies who are severely immu-
nocompromised have a particular risk of these infec-
tions. 
In this case-control study we aimed to identify 
which species of dermatophyte are causing infec-
tions in patients diagnosed with neoplastic diseases 
and also to assess in vitro susceptibility of isolated 
dermatophytes in these patients to itraconazole (ITZ), 
ketoconazole (KTZ), fluconazole (FLZ), voriconazole 
(VCZ), and terbinafine (TBF). We compared the find-
ings with those in immunocompetent patients. 
PATIENTS AND METHODS
138 patients (71 men and 67 women, sex ratio 
M/F 1.06) diagnosed with various malignancies that 
were referred for dermatophyte infections to the 
Department of Dermatology of the Clinical County 
Emergency Hospital in Brasov, Romania were includ-
ed in this study. Only patients who had not recieved 
any immunosuppressive therapy or radiotherapy in 
the last 6 months were included in the study. Ma-
lignancies diagnosed in study group are shown in 
Table 1. The mean age of this group (expressed as 
mean±standard deviation, SD) was 58.84±13.08 years, 
with a range between 8 and 83 years. The mean dura-
tion of the evolution of neoplasia at time of diagnosis 
was 3.17±1.96 years. In parallel, a control group con-
sisting of 160 immunocompetent patients (84 men 
and 76 women, sex ratio M/F 1.10) aged between 18 
and 78 years (average age 56.42±11.70 years) who 
showed signs of fungal infections was also analyzed. 
Pathological material was collected by clipping the 
nail or scraping the skin lesions from each patient 
from both groups. 
The specimens taken from infected areas were 
examined by direct microscopy. Positive specimens 
were then cultured in a Sabouraud dextrose agar me-
dium with addition of cycloheximide, chlorampheni-
col, and gentamicin (Bio-Rad, France) and incubated 
at 30°C for 2-4 weeks. Dermatophyte species were 
identified according to macroscopic and microscopic 
criteria of colonies developed in the culture medium.
Susceptibility to antifungals was tested using a 
broth microdilution method according to the criteria 
of M38-P of the Clinical and Laboratory Standards In-
stitute (CLSI) for filamentous fungi (1). Five antifungal 
substances were used for testing in vitro susceptibil-
ity of isolated dermatophytes: itraconazole (Janssen 
Research Foundation, Beerse, Belgium), ketoconazole 
(Janssen Research Foundation, Beerse, Belgium), flu-
conazole (Pfizer Inc., New York, USA), voriconazole 
(Pfizer Inc., New York, USA), and terbinafine (Novartis, 
Basel, Switzerland). ITZ, KTZ, FLZ, and VCZ were dis-
solved in a 100% dimethyl sulfoxide solution, and TBF 
was prepared in dimethyl sulfoxide solution with 5% 
Tween 80 according to the protocol of Jessup et al. (2). 
To reduce the initial concentration of each antifun-
gal 100 times, ten serial twofold dilutions were per-
formed. Concentrations of serial drug dilutions ranged 
from 0.0078 to 4 μg/mL for VCZ and TBF, to 0.0625 to 
32 μg/mL for KTZ and ITZ, and 0.125 to 64 μg/mL for 
FLZ. The initially obtained colonies of dermatophytes 
were recultured in Sabouraud agar medium at 30°C 
for 7-15 days, the time necessary to achieve sporula-
tion. The plates with Sabouraud agar medium were 
covered with sterile normal saline (0.9%), after which 
the dermatophyte colonies were gently scraped with 
a sterile loop. The suspension consisting of fragments 
of conidia and hyphae was transferred to a sterile 
tube. For sedimentation of heavy particles, the tube 
was left at room temperature for 15-20 minutes and 
then the upper suspension was centrifuged at 2000 
rpm for 15 seconds. The supernatant was further di-
luted to 1:50 in buffered RPMI 1640 solution and stan-
dardized spectrophotometrically to approximately 
0.5 McFarland units at a wavelength of 520 nm and a 
transmission of 70-80% to the desired concentration 
of 0.5-5×104 colony-forming units (CFU)/mL for final 
test inoculums. RPMI 1640 medium (Sigma-Aldrich) 
buffered at pH 7.0 with 0.165 mol/L 3-(N-morpholino) 
propanesulphonic acid (MOPS) was used for sensi-
tivity tests for antifungals. The sensitivity tests were 
performed in sterile, round-bottomed, 96 U-shaped 
well microplates, each well with a nominal capacity 
of 300 μL. Alliquots of 100 μL of the serial 2-fold dilu-
tions of the antifungal substance and then 100 μL of 
the diluted inoculums suspensions were added into 
each well in columns 2 to 11. The first column wells 
Table 1. The frequency of dermatophyte infec-
tions in neoplastic patients with neoplastic dis-
eases
Neoplasia No. of patients
Dermatophyte 
infection rate
Colorectal carcinoma 23 26.1%
Breast cancer 22 22.7%
Gastric adenocarcinoma 17 35.3%
Leukemia 16 68.7%
Prostate adenocarcinoma 13 23.1%
Lymphoma 11 36.4%
Cervical cancer 11 18.2%
Ovarian cancer 8 12.5%
Lung carcinoma 7 28.6%
Squamous cell carcinoma 4 25.0%
Melanoma 3 33.3%
Hepatocellular carcinoma 2 0.0%
Esophageal cancer 1 0.0%
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were filled with 200 μL of RPMI 1640 medium serving 
as sterility control. 100 μL of inoculum solution and 
100 μL of RPMI 1640 medium were distributed in the 
twelfth column’s wells, serving as growth control. T. 
mentagrophytes (ATCC MYA-4439), Candida parapsilo-
sis (ATCC 22019), T. rubrum (ATCC MYA-4438), and also 
Candida krusei (ATCC 6258) were included as quality 
control. Microdilution plates were incubated at 30°C 
for 7 days. Rate of growth in each well was visually 
assessed daily, starting 48 hours after inoculation, 
based on comparison with growth in sterility controls 
and growth controls, respectively.
Mean minimum inhibitory concentrations (MIC), 
MIC50, and MIC90 were determined for each antifungal 
agent for each dermatophyte species isolated among 
control group subjects and in the patient group. In 
accordance with the broth microdilution method 
proposed in CLSI M38-P protocol (1), the minimal 
inhibitory concentration was defined as the lowest 
concentration that showed 100% growth inhibition 
for TBF and 80% for azoles compared with the growth 
controls (3,4). A dermatophyte species was consid-
ered resistant to an antifungal agent when MIC was 
≥4 μg/mL for ITZ, VCZ, and TBF, ≥8 μg/mL for KTZ, 
and ≥64 μg/mL for FLZ, according to the criteria of 
CLSI M38-P (1). Statistical differences in the frequency 
patterns of dermatophyte species between patients 
with malignancy and the control group was assessed 
using Fisher’s exact chi-square test. Student’s t-test 
was used for calculate the significance of the differ-
ence between the mean values of MICs of the five 
antifungal substances tested in the abovementioned 
groups. A value of P less than 0.05 was considered sig-
nificant. 
RESULTS
Following the mycological investigations among 
the 138 patients with neoplastic diseases, positive 
samples for dermatophyte infections were found in 
42 patients (30.4%), for Candida spp. in 14 patients 
(10.14%), and for Aspergillus in one patient (0.72%). 
Frequency of dermatophyte infections according 
to type of neoplasia is shown in Table 1. The gender 
distribution of dermatophyte infections in patients 
with neoplastic diseases was approximately equal: 
29.85% for women and 30.98% for men. Tinea ungui-
um was the most frequent clinical form of dermato-
phytosis encountered in 19 of the 42 patients (45.2%) 
with malignancies and dermatophyte infection, fol-
lowed by tinea pedis in 10 patients (23.8%), tinea cru-
ris and tinea corporis in 4 patients each (9.5%), tinea 
manum in 2 patients (4.8%), and tinea faciei, tinea ca-
pitis, and tinea barbae in one patient each (2.4%). 
Dermatophyte and candidal infection rates in the 
control group were 29.37% (47 patients) and 5.6% (9 
patients), respectively. Tinea unguium was also the 
most frequent clinical form of dermatophytosis in the 
control group, found in 21 cases (44.7%), followed 
by tinea pedis in 14 patients (29.8%), tinea cruris in 
6 patients (12.8%), tinea corporis in 3 patients (6.4%), 
and tinea manum, tinea barbae and tinea faciei in 1 
patient each (2.1%).
Etiological agents depending on the clinical form 
of dermatophytosis in both groups of patients are 
shown in Table 2. T. rubrum was the most frequently 
isolated agent in both groups. There were no statisti-
cally significant differences in the frequency patterns 
of T. rubrum, M. canis, T. mentagrophytes and E. floc-
cosum between the two groups (p> 0.05).
The MIC statistics including mean MIC, MIC50, and 
MIC90 values of ITZ, KTZ, FLZ, VCZ, and TBF for T. ru-
brum, M. canis, T. mentagrophytes, and E. floccosum in 
patients with neoplasia and in the control group are 
shown in Table 3. Mean MIC values of all the antifungal 
Table 2. Etiological agents and clinical forms of dermatophyte infections in both groups
T. rubrum T. mentagrophytes M. canis E. floccosum Total
Neoplasia Control Neoplasia Control Neoplasia Control Neoplasia Control Neoplasia Control
Tinea unguium 18 19 1 2 - - - - 45.2% 44.7%
Tinea pedis 7 11 2 2 - - 1 1 23.8% 29.8%
Tinea cruris 3 4 1 1 - - - 1 9.5% 12.8%
Tinea corporis 2 2 - - 2 1 - - 9.5% 6.4%
Tinea manum 2 1 - - - - - - 4.8% 2.1%
Tinea faciei - - - - 1 1 - - 2.4% 2.1%
Tinea capitis - - - - 1 - - - 2.4% 0%
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drugs studied for all of dermatophyte species isolat-
ed from the neoplastic patients were similar to mean 
MIC that was obtained in the control group (p>0.05). 
TBF had the lowest, and FLZ the highest mean MIC, 
MIC50, and MIC90 values for all dermatophytes tested 
in the two groups. One case of resistance to FLZ of a 
T. mentagrophytes strain isolated from a patient with 
neoplasia was recorded. The patient had previously 
received repeated treatments with fluconazole for 
recurrent candidal infections. In vitro activity of KTZ, 
ITZ, VCZ, FLZ, and TBF against dermatophytes in pa-
tients with neoplasia was similar to that of immuno-
competent patients. 
DISCUSSION
Although fungal infections do not cause epidemic 
or pandemic outbreaks, their incidence has increased 
significantly, mainly due to the increasing number of 
patients with compromised immune system. Derma-
tophyte infections in immunocompromised patients 
are often disseminated, asymptomatic, and refractory 
to treatment. In this context, accuracy and precocity 
of diagnosis become essential for epidemiological 
purposes and to establish proper treatment, and sus-
ceptibility testing is mandatory although the corre-
lation between in vitro tests and in vivo therapeutic 
response has not been completely defined.
In this study, we investigated the dermatophyte 
species causing dermatophyte infections, and the 
in vitro susceptibility of those dermatophytes to ITZ, 
KTZ, FLZ, VCZ, and TBF in patients with neoplasia and 
compared the results with those in immunocompe-
tent individuals. We have not noticed any difference 
in the frequency of dermatophyte infections in pa-
tients with neoplastic diseases (30.4%) compared 
to immunocompetent patients (29.37%). Tinea un-
guium was the most frequent clinical form of der-
matophyte infection encountered in 19 of the 42 
patients (45.2%) with neoplasia and dermatophytic 
infection. Our findings indicate that, similar to the 
immunocompetent population, T. rubrum was the 
principal agent responsible for dermatophyte infec-
tion in patients with neoplastic diseases, followed by 
M. canis. Moulds and yeast infections were diagnosed 
in 0.72% and 10.14% of patients with malignancies, 
respectively. In one case there was a mixed infection 
of the nail with Candida albicans and T. rubrum. In ex-
ceptional circumstances mixed fungal infections may 
exist, their archetype being the association of Scopu-
lariopsis brevicaulis and T. rubrum in onychomycosis. 
Table 3. Mean minimum inhibitory concentration (MIC) values of antifungals for all of the isolated derma-
tophyte species in both groups 
Antifungal Dermatophyte species 














T. rubrum 0.19 0.172 0.15 0.062 1 1
T. mentagrophytes 0.75 0.65 0.5 0.5 1 1
M. canis 0.8 0.67 1 0.5 1 1
E. floccosum 0.5 0.375 0.25 0.25 0.5 0.25
Itraconazole 
T. rubrum 0.118 0.08 0.062 0.062 0.5 0.5
T. mentagrophytes 0.156 0.0875 0.125 0.062 0.25 0.125
M. canis 0.275 0.33 0.25 0.062 0.5 0.5
E. floccosum 0.125 0.094 0.125 0.0625 0.125 0.125
Fluconazole 
T. rubrum 6.1 6.6 4 4 8 8
T. mentagrophytes 26 10.4 16 8 64 16
M. canis 12.8 10.6 16 8 16 16
E. floccosum 4 3 4 2 4 4
Voriconazole 
T. rubrum 0.15 0.11 0.062 0.062 0.5 0.25
T. mentagrophytes 0.312 0.275 0.25 0.25 0.5 0.5
M. canis 0.225 0.208 0.25 0.25 0.25 0.25
E. floccosum 0.125 0.0625 0.125 0.0625 0.125 0.0625
Terbinafine 
T. rubrum 0.009 0.008 0.007 0.007 0.031 0.015
T. mentagrophytes 0.023 0.021 0.015 0.015 0.031 0.031
M. canis 0.034 0.041 0.031 0.031 0.062 0.062
E. floccosum 0.062 0.046 0.062 0.015 0.062 0.062
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The combination of Mucor spp. and Candida spp. in 
with patients neoplastic diseases has also been re-
ported in the literature (5).
Patients with lymphoma or leukemia are more 
susceptible to deep fungal infections in periods with 
severe neutropenia following chemotherapy or bone 
marrow transplantation (6,7). In our study, there was 
a significantly higher frequency of dermatophyte in-
fections in patients with hematological malignancies 
(55.5%) compared to those with solid cancers (24.3%), 
similarly to Altay et al. who also found a significantly 
higher incidence of fungal infections of 70% in pa-
tients with hematologic malignancies compared with 
healthy patients, but with Candida albicans being the 
prevalent mucosal infection (8). Patients with solid 
tumors who are treated with radiation or chemother-
apy in small doses have a lower risk of developing 
dermatophytosis (9). 
The patients’ age and comorbidities, such as dia-
betes mellitus (10), psoriasis (11), Cushing syndrome, 
malnutrition, alcoholism, drugs abuse, and genetic 
diseases with immune deficiencies, may favor the 
emergence of dermatophytosis, especially of ony-
chomycosis (12).
Systemic antifungal treatment is the therapy of 
choice for dermatophytosis (13). Although the thera-
peutic efficacy of itraconazole (ITZ), ketoconazole 
(KTZ), fluconazole (FLZ), voriconazole (VCZ), and ter-
binafine (TBF) is well known for the general popula-
tion with dermatophytosis, there are limited data for 
patients with neoplastic diseases. 
The main difficulty in treating patients with neo-
plastic diseases is selecting of the most effective an-
tifungal drug.The use of this therapy may result in 
undesirable side-effects that can be particularly dan-
gerous in patients with malignancies. Although most 
clinical trials on immunocompetent patients show 
that TBF has higher cure and lower relapse rates (14), 
less data are available about its efficacy in patients 
with neoplastic diseases. Our data reveal that all test-
ed antifungal drugs are effective against T. rubrum, M. 
canis, T. mentagrophytes and E. floccosum in patients 
with neoplastic diseases, but TBF has higher antider-
matophyte activity with much lower mean MIC than 
other antifungals, and FLZ was the least efficient an-
tifungal drug, in addition to a strain of T. mentagro-
phytes resistant to FLZ being identified in a patient 
with neoplasia. 
CONCLUSION
Since TBF was the most active antidermatophyte 
drug in vitro, and considering that its higher antide-
rmatophyte activity compared with azoles and its 
drug interactions do not typically cause problems, 
we believe TBF should be the therapy of choice for 
dermatophytosis in patients with neoplastic diseases. 
However, larger studies are required to assess the 
safety of antifungal drugs administration in patients 
with malignancies. 
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